Alpha Tau to discuss interim results of Alpha DaRT treatment for recurrent glioblastoma in US trial

Alpha Tau Medical will hold a conference call on May 11, 2026, to discuss interim clinical data from the first three patients treated with its Alpha DaRT alpha-radiation therapy in a US trial for recurrent glioblastoma. The REGAIN trial aims to evaluate the safety and feasibility of this innovative treatment for patients with recurrent glioblastoma who cannot undergo surgery. Alpha DaRT delivers targeted alpha radiation to destroy tumors while sparing healthy tissue. The trial plans to enroll up to ten patients, with results potentially advancing treatment options for this aggressive brain cancer.